Method for inducing cell death in acute lymphoblastic leukemic system cells
The present invention provides agents comprising or consisting of a binding moiety with specificity for interleukin-1 receptor accessory protein (IL1RAP) for use in inducing cell death and/or inhibiting the growth and/or proliferation of pathological stem cells and/or progenitor cells associated with a neoplastic hematologic disorder, wherein the cells express IL1RAP. A related aspect of the invention provides agents comprising or consisting of a binding moiety with specificity for interleukin-1 receptor accessory protein (IL1RAP) for use in detecting pathological stem cells and/or progenitor cells associated with a neoplastic hematologic disorder, wherein the cells express IL1RAP. Further provided are pharmacological compositions comprising the agents of the invention and methods of using the same.
1. A method for inhibiting human interleukin-1 receptor accessory protein (IL 1 RAP) associated signaling on pathological stem cells and/or progenitor cells expressing IL 1 RAP in an individual with a neoplastic hematologic disorder, wherein the neoplastic hematologic disorder is leukemia, the method comprising administering to the individual an effective amount of an antibody comprising a binding specificity for IL 1 RAP, and the leukemia is acute lymphoblastic leukemia (ALL).
2. The method according to claim 1 wherein the antibody comprises an antibody or antibody fragment.
3. The method according to claim 2 wherein the antibody or antibody fragment is human or humanized.
4. The method according to claim 3 wherein the antibody or antibody fragment comprises an Fc region from an IgG1 or an IgG3 antibody.
5. The method according to claim 1 wherein the antibody further comprises a cytotoxic moiety.
6. A method for inhibiting IL 1 RAP associated signaling on pathological stem cells and/or progenitor cells in an individual with the neoplastic hematologic disorder acute lymphoblastic leukemia (ALL), the method comprising administering to the individual an effective amount of an antibody comprising a specificity for IL 1 RAP.
7. The method according to claim 6 wherein the antibody comprises an antibody or antibody fragment.
8. The method according to claim 7 wherein the antibody or antibody fragment is human or humanized.
9. The method according to claim 8 wherein the antibody or antibody fragment comprises an Fc region from an IgG1 or an IgG3 antibody.
10. The method according to claim 7 wherein the antibody or antibody fragment further comprises a cytotoxic moiety.